The approval of Beigene's drug Tevimbra by the European Commission is a significant milestone for the company. This approval allows the company to market and sell the drug in the European Union, potentially increasing its market share and revenues. Given the size of the European market, this approval could have a significant positive impact on Beigene's stock price in the short term.